Spero Therapeutics Inc

NASDAQ:SPRO   3:59:57 PM EDT
2.00
-0.20 (-9.09%)
5:24:31 PM EDT: $2.00 0.00 (0.00%)
Products

Spero Therapeutics provides Tebipenem HBR Program Update following Type A meeting with the U.S. FDA

Published: 09/06/2022 12:19 GMT
Spero Therapeutics Inc (SPRO) - Spero Therapeutics Provides Tebipenem Hbr Program Update Following Type a Meeting With the U.S. Food and Drug Administration.
Plans to Advance Tebipenem Hbr's Clinical Development and Potential Commercialization Through External Partnership.
FDA Feedback Indicates Positive Results From a Single Additional Phase 3 Clinical Trial in Patients With Complicated Uti.